The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Interventions for valvular disease and heart failure

Will the PARTNER 3 Low Risk Trial change my practice?

EuroIntervention 2019;15:e1077-e1080. DOI: 10.4244/EIJ-D-19-00847

1. Royal Berkshire NHS Foundation Trust, Reading, United Kingdom; 2. Centre Hospitalier Régional Universitaire de Lille, Lille, France; 3. Montefiore Medical Center, New York City, NY, USA; 4. Applied Health Research Centre, Li Ka Shing Knowledge Institute of St. Michael’s Hospital, University of Toronto, Toronto, Canada; 5. Bern University Hospital, University of Bern, Bern, Switzerland; 6. Columbia University Medical Center, New York, NY, USA


The aim of this article is to capture the session at EuroPCR 2019, communicate the analysis of the trialists, and report the views expressed in the interactive discussion.

Introduction to the session

The last 17 years represent an unparalleled era of technological design and device iterations for valve intervention. Transcatheter aortic valve implantation (TAVI) has been explored in randomised controlled trials (RCTs) in an inverse fashion when compared with coronary angioplasty - starting with extreme- and high-risk patients, and progressively moving towards low-risk patients (Figure 1).


Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent versus a durable fluoropolymer-based everolimus-eluting stent in patients with coronary artery disease: the ANGIOLITE trial